Opinion / How Patent Analytics Can Show Pharma's Top Performers
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
Address: Am Karlsbad 15 / 10785 Berlin
Tel: +49 (0) 30 2639 2880
Cytolon is the first technology company to fulfill the central needs of personalized medicine. Personalized medicine is based on matching the patient´s personal genomic and histocompatibility data with the characteristics of a given product in order to achieve the best possible therapeutic effect. As medical treatments become more personalized, it will be increasingly important to be able to provide fast and accurate matching of patient data with therapeutic products for hundreds of thousands of patient cases at any time. A comprehensive solution can only be provided by intelligent internet-based matching platforms. As of today, there are no matching platforms that fulfill these needs. Cytolon was created to fill this gap.
Cytolon´s corporate mission is to be the world’s first trusted source for obtaining the correct, best-matched personalized product in a timely and cost-effective manner. Cytolon meets the requirements of personalized medicine through high performance matching, comprehensive logistics and secure data management for clinical development.
As allogeneic cord blood units and the stem cells contained within them are the first existing personalized products in clinical practice, Cytolon is initially focusing on this market. An accurate, timely matching process is imperative as a cord blood unit (CBU) must perfectly match the histocompatibility antigens and genetic needs of the patient and must be delivered within days.
Cytolon has developed a proprietary, patent-pending, global internet-based cord blood matching platform called CordMatch®. This platform is unique, as it integrates product search and matching, selection and logistics plus billing and follow-up.
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
The latest pharma industry news from Germany, including German lobbying efforts against EU pharma legislation; Evonik’s new lipid manufacturing plant; Bayer’s 2023 sales and earnings outlook; Boehringer Ingelheim new biotech…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
See our Cookie Privacy Policy Here